An announcement from AngioDynamics ( (ANGO) ) is now available.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
AngioDynamics reported its fiscal year 2025 second-quarter financial results, highlighting a 9.2% increase in net sales driven by strong performance in its Med Tech segment, which grew by 25%. The company achieved key milestones for its NanoKnife System, receiving CPT Category I Codes and FDA 510(k) clearance for prostate tissue ablation, positioning it for accelerated growth. Despite a GAAP net loss, AngioDynamics showed improved adjusted earnings, raised its fiscal year guidance, and saw positive developments in its NanoKnife technology, enhancing its market positioning and reimbursement prospects.
More about AngioDynamics
AngioDynamics, Inc. is a leading medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving the quality of life for patients.
YTD Price Performance: 4.68%
Average Trading Volume: 532,612
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $376.7M
For a thorough assessment of ANGO stock, go to TipRanks’ Stock Analysis page.
